Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, Alibaba is a Chinese company and has huge market share in China. Many people don't know Tollovid yet in China. Once knowing Tollovid function on Covid, they will buy like crazy.
Here is what I speculate why Gerald is in a hurry to buy out NLC pharma before phase 2 data realease. Recent research by NLC could identif y a specific compound in Tollovir or root extract that acts as ligand to efficiently bind to 3CL protease and this compound or chemical could be chemically synthesized in a large quantity in lab instead of growing plants in field. Gerald mentioned in his tweet early that Toros identifies specific ligand binding 3CL Protease. Now they talk about next generation of anticovid drug in news release. I speculate this is what is going on now. Gerald also mentioned in his tweet that Todos will buy out the remaining 40% of new sub from Dr. Arad when listed in Nasdaq.
I bet >$5 for tomdf and let's see what will unfold.
You are a great trader. I just buy and hold for a long term especially avax, sand, mana.
I have sand, avax, mana, gala , req, lrc and they are volatile recently. Tomdf performance outpaces my coins this week.
Yes
This dip gives people who missed 4 or 5 cents an opportunity to load. I know a few of my OTC multimillionair friends who are interested in tomdf and they might start loading.
I did my DD and started loading since sometime Oct. Drug works and effective and safer than Pfizer's one. Covid will not go away in a few years and vaccines are not strong enough to prevent infection and spreading. Effective anticovid drugs will be only way to get us to normal life.
People keep adding at this level and whoever sold now will regret late. I feel sorry for folks who sold me their shares at 3 and 4 cents a few days ago. It will be over $1 soon and drug is there and market is their.
Consolidation from 4 to 9 cents and dollarland and next.
Flippers want cheap shares and SP will be in multi-dollar territory. Add and hold since 4 cents.
Many people are waiting while others are quite loading. It was about 1-3 million trading volume even a few days ago and now volume picks up. We will see over billion trading volume once phase 2 data is released.
I agree with your points.
That could be old information. If I recall correctly, GC mentioned the compound other than Skikonin is responsible for binding to 3CL Protease.
Do your DD. Pfizer's positive clinical data increases $20 billions in value. Similar scale increase of valuation could put tomdf around $20, considering 900 million OS. Tollovir is as effective as Pfizer's drug but much safer than it.
No, hold my shares very tightly until multi-dollar land
As CEO indicated in early, major anticovid compound in Tollovir is not Shikonin. Shikonin is a nonspecific antiviral compound and has a low binding affinity to 3CL Pro. But Shikonin also has anti-cytokine effect and I guess it could primarily contribute to anti-inflammatory function in Tollovir if any.
Do you notice lack of trading activity in TDA for over 20 minutes?
Hold my shares and anticipate at least $5. Potential buyout by other company. Anticovid drug market will be huge in next decades and vaccines can't get rid of it and can't prevent reinfection.
Stellar clinical data will push MC to potential $multi-billion territory and that will take care of everything. At this stage, sec filling and financial are irrelevant. This is bio stock and succeful drug really dictates the trajectory of stock price.
Great information for osci
Don't need R/S to get $5-10 target. Pfizer's positive news increased MC by $25 billions. We just need $5-10 billion MC. Or Merck may buy out at $5-10 billion range.
That is my target too.
What is going on here? See big drop this morning.
Veru positive messenger.
Very confident that this stock will make many multimillionaires here.
Agree, highly likely Todos will be eventually bought out by a big pharm. Accumulating cheap shares now.
I bought 20 millions of wogi when at 0.0020 sometime last year and sold around 0.005 but did not hold. Wish I held a part of my shares.
A potential buyout candidate:
“---Merck could easily get back in the race if they go after and partner with one of these dark horse candidates, Todos Medical or CytoDyn. Using their expertise, they could get these valuable assets across the finish line faster than the smaller companies could. These fledgling biotechs with powerful technologies may be just what the doctor ordered for Merck to continue competing for the leading position in the fight against COVID-19---”.
This is not gamble now. Pfizer data shows 3CL pro is an ideal target and the phase 1 data is very positive. I am scientifically convinced!
Doing the same thing and keep adding daily. My average is around 4 cents now. Many folks will chase late instead of accumulating now.
Tollovid possesses two actions: Inhibit 3CL pro to perturb polypeptide maturation by a ligan company found but not reveal it yet and repress inflammatory reaction by secondary metabolite likely Shikonin. From recent review article, it is known that shikonin has numerous pharmacological properties, including anti-inflammatory, anti-fungal, and anti-HIV effects.
Like what it is said in the article:
“---Todos’ drug is called Tollovir, and in its exploratory observational study, it showed a 100% mortality benefit and got people out of the hospital sooner. There is a proper phase 2 readout expected before the end of the year and it could shake up the markets because PAXLOVID and Tollovir are going after the same druggable target, Mpro. Results mirroring the observational study and sort of in alignment with PAXLOVID’s demonstrated robust efficacy will be strong evidence that Todos indeed has the secret sauce. Many investors don’t realize this or are hung up on the observational study not being a proper placebo-controlled phase 2, which is why the stock sold off in sympathy with all the other oral antivirals on the Pfizer news. The reality is that Todos’ drug, with Pfizer’s data and its observational study, looks like it could knock it out of the park on its upcoming phase 2 data, expected before December rolls around.”.
Tomdf, a potential dark horse in anticovid drug space!
$tomdf Today's New Seeking-Alpha article stating a potential dark horse in $multi-billion's anticovid drug space compared to Merck's Molnupiravir and Pfizer's PAXLOVID. $43 million MC.$mrk $pfe $enzc $tggi $rgbp $hmbl $mwwc $tonr$shib $ada $bnb $mara https://t.co/QSjm9vEILv
— Zach (@ZZach1958) November 9, 2021
Pfizer's positive data released last week increased MC by at least $20 billions. Tollovir targets the same 3CL Pro plus anti-inflammatory function, which ,I assume, is better than Pfzer's anticovid drug. Based on phase 1 trial data, I expect great data from phase 2 trial, which could increase MC by a scale similar to that of Pfizer.
More than your target. 5-10 long term.
Oversold
Also means people start loading here.
Means a lot multi-millionaires here soon.
Nice information
Added 100K too